These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

753 related items for PubMed ID: 1293793

  • 1. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD, González FA, Villegas A, del Potro E, Díaz Mediavilla J, Martínez R, Alvarez A, Colomé JA.
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [Abstract] [Full Text] [Related]

  • 2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 3. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL, Fiacchini M, Mazza P, Gherlinzoni F, Bocchia M, Tura S.
    Haematologica; 1991 Sep; 76(4):305-10. PubMed ID: 1724437
    [Abstract] [Full Text] [Related]

  • 4. Hodgkin's disease: summary of twenty years' experience.
    Mazza P, Bocchia M, Zinzani PL, Fiacchini M, Gherlinzoni F, Bandini G, Bendandi M, Frezza GP, Neri S, Barbieri E.
    Haematologica; 1992 Sep; 77(6):487-93. PubMed ID: 1283856
    [Abstract] [Full Text] [Related]

  • 5. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650
    [Abstract] [Full Text] [Related]

  • 6. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R, Anselmo AP, Osti MF, Santoro M, Tombolini V, Mandelli F, Biagini C.
    Haematologica; 1997 Sep 15; 82(1):57-63. PubMed ID: 9107084
    [Abstract] [Full Text] [Related]

  • 7. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct 15; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 8. Second malignant tumours in childhood Hodgkin's disease.
    Jenkin D, Greenberg M, Fitzgerald A.
    Med Pediatr Oncol; 1996 Jun 15; 26(6):373-9. PubMed ID: 8614372
    [Abstract] [Full Text] [Related]

  • 9. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 10. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.
    Sangre (Barc); 1998 Jun 01; 43(3):179-84. PubMed ID: 9741222
    [Abstract] [Full Text] [Related]

  • 11. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 12. Second malignancy complicating Hodgkin's disease.
    Tawil E, Mercier JP.
    J Can Assoc Radiol; 1983 Jun 15; 34(2):108-13. PubMed ID: 6688422
    [Abstract] [Full Text] [Related]

  • 13. Hodgkin's disease and acute leukemia. Is it a true association?
    Avilés A, Díaz-Maqueo JC, Ayala JR, Cortés HD, García EL.
    Arch Med Res; 1992 Jun 15; 23(1):65-8. PubMed ID: 1308794
    [Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
    [Abstract] [Full Text] [Related]

  • 15. High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
    Corti C, Theodore C, Bayle C, Rougier P, Nasr F, Cosset JM, Girinsky T, Hayat M, Ribrag V.
    Hematol Oncol; 1996 Dec 01; 14(4):159-63. PubMed ID: 9267461
    [Abstract] [Full Text] [Related]

  • 16. [Non-Hodgkin's lymphoma secondary to Hodgkin's disease treated with chemo- and radiotherapy. Report of a case].
    Gamboa Domínguez A, Pita Ramírez L, Hurtado Monroy R, Angeles-Angeles A.
    Rev Invest Clin; 1992 Dec 01; 44(3):393-8. PubMed ID: 1283228
    [Abstract] [Full Text] [Related]

  • 17. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):19-30. PubMed ID: 17097834
    [Abstract] [Full Text] [Related]

  • 18. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, Henry-Amar M.
    J Clin Oncol; 2006 Jul 01; 24(19):3128-35. PubMed ID: 16754934
    [Abstract] [Full Text] [Related]

  • 19. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG, Pieresca C, Cavanna L, Corbella F, Vallisa D, Federico M, Formisano R, Carotenuto M, Merli F, Callea V, Angrilli F, Silingardi V.
    Haematologica; 1996 Jul 01; 81(6):503-12. PubMed ID: 9009437
    [Abstract] [Full Text] [Related]

  • 20. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S, Geara F, Nabbout B, Farah RA, Shabb NS, Hajjar T, Khogali M.
    Radiat Oncol Investig; 1999 Jul 01; 7(6):365-73. PubMed ID: 10644060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.